Results 81 to 90 of about 10,682 (172)

Fatty acid metabolism—an emerging regulatory node in T‐cell immunometabolism

Clinical &Translational Immunology, Volume 15, Issue 4, 2026.
Abstract While the roles of glucose metabolism and tricarboxylic acid (TCA) cycle intermediates in immune regulation are well established, the contribution of fatty acid metabolism remains less well defined. In this review, we examine current knowledge on the immunomodulatory functions of fatty acid metabolism, with a particular focus on T‐cell biology.
Brett Chapel Arenberg, Michael N Sack, Jing Wu   +2 more
wiley   +1 more source

Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model

Neurobiology of Disease, 2004
Brain cannabinoid CB1 receptors are expressed in neural areas that contribute to movement such as basal ganglia, where they co-localize with dopamine D1 and D2 receptors.
Fadwa El Banoua, Isabel Caraballo, Juan A Flores, Beatriz Galan-Rodriguez, Emilio Fernandez-Espejo   +4 more
doaj   +1 more source

Epilepsy: Molecular Pathogenesis and Emerging Therapies

MedComm, Volume 7, Issue 4, April 2026.
Progress has been made in the molecular pathogenesis of epilepsy, revealing multiple therapeutic targets. Recent advances in pharmacology, materials science, and surgical technique, coupled with progress in targeted therapy and disruptive epilepsy network technology, have led to the emergence of innovative strategies for epilepsy treatment.
Wanbin Huang, Jiabin Zong, Yu Zhang, Ming Li, Songqing Pan, Zheman Xiao   +5 more
wiley   +1 more source

Development of a novel risk score reflecting the relative harm potential of synthetic cannabinoids based on prevalence estimates, well‐documented intoxication cases and basic pharmacological data

Addiction, Volume 121, Issue 4, Page 870-882, April 2026.
Abstract Background and aims While the health hazards of synthetic cannabinoid receptor agonists (SCRAs) are often approximated using in vitro pharmacological parameters as surrogate, this approach fails to consider pharmacokinetic and pharmacodynamic complexity.
Michaela J. Sommer, Katharina Elisabeth Grafinger, Maren Hermanns‐Clausen, Volker Auwärter   +3 more
wiley   +1 more source

Cannabinoid Receptor Activation Disrupts the Internal Structure of Hippocampal Sharp Wave–Ripple Complexes

Journal of Pharmacological Sciences, 2012
Cannabinoid agonists impair hippocampus-dependent learning and memory. Using mouse hippocampal slice preparations, we examined the effect of anandamide, an endogenous cannabinoid, on sharp wave–ripple (SW-R) complexes, which are believed to mediate ...
Yi Sun, Hiroaki Norimoto, Xiao-Ping Pu, Norio Matsuki, Yuji Ikegaya   +4 more
doaj   +1 more source

Cannabinoid 1 Receptor Signaling on Hippocampal GABAergic Neurons Influences Microglial Activity

Frontiers in Molecular Neuroscience, 2018
Microglia, the resident immune cells of the brain, play important roles in defending the brain against pathogens and supporting neuronal circuit plasticity.
Frank Ativie, Joanna A. Komorowska, Eva Beins, Önder Albayram, Till Zimmer, Andreas Zimmer, Dario Tejera, Michael Heneka, Andras Bilkei-Gorzo   +8 more
doaj   +1 more source

Revealing the therapeutic potential of synthetic cannabinoids: a systematic review of cannabinoid receptor binding dynamics and their implications for cancer therapy

Journal of Cannabis Research
Background Cancer remains a major global health issue, prompting the need for innovative treatment approaches that extend beyond conventional methods such as chemotherapy and radiation.
Sahar S. Alghamdi, Hussah N. Albahlal, Danah E. Aloumi, Sarah Bin Saqyah, Arwa Alsubait, Jehan Alamre, Mohammed Alrashed, Nada Alsuhabeny, Afrah E. Mohammed   +8 more
doaj   +1 more source

The Endocannabinoid System and Oligodendrocytes in Health and Disease

Frontiers in Neuroscience, 2018
Cannabinoid-based interventions are being explored for central nervous system (CNS) pathologies such as neurodegeneration, demyelination, epilepsy, stroke, and trauma. As these disease states involve dysregulation of myelin integrity and/or remyelination,
Alexander A. Ilyasov, Alexander A. Ilyasov, Carolanne E. Milligan, Carolanne E. Milligan, Emily P. Pharr, Emily P. Pharr, Allyn C. Howlett, Allyn C. Howlett   +7 more
doaj   +1 more source

Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure

Pharmaceuticals, 2018
Nearly half a century has passed since the demonstration that cannabis and its chief psychoactive component Δ9-THC lowers intraocular pressure (IOP).
Sally Miller, Shashank Kulkarni, Alex Ciesielski, Spyros P. Nikas, Ken Mackie, Alexandros Makriyannis, Alex Straiker   +6 more
doaj   +1 more source

CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist

Frontiers in Pharmacology, 2019
Synthetic cannabinoid receptor agonists (SCRAs) are the largest class of new psychoactive substances (NPS). New examples are detected constantly, and some are associated with a series of adverse effects, including seizures.
Richard C. Kevin, Richard C. Kevin, Richard C. Kevin, Lyndsey Anderson, Lyndsey Anderson, Lyndsey Anderson, Iain S. McGregor, Iain S. McGregor, Iain S. McGregor, Rochelle Boyd, Jamie J. Manning, Michelle Glass, Mark Connor, Samuel D. Banister, Samuel D. Banister, Samuel D. Banister   +15 more
doaj   +1 more source